Home/Filings/4/0000902664-24-006775
4//SEC Filing

Slate Path Capital LP 4

Accession 0000902664-24-006775

CIK 0001755237other

Filed

Nov 24, 7:00 PM ET

Accepted

Nov 25, 4:05 PM ET

Size

7.9 KB

Accession

0000902664-24-006775

Insider Transaction Report

Form 4
Period: 2024-11-21
Transactions
  • Sale

    Common Stock, no par value

    2024-11-21$1.55/sh357,880$555,1080 total(indirect: See footnote)
Transactions
  • Sale

    Common Stock, no par value

    2024-11-21$1.55/sh357,880$555,1080 total(indirect: See footnote)
Footnotes (2)
  • [F1]The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023.
  • [F2]The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

Documents

1 file

Issuer

Cyclerion Therapeutics, Inc.

CIK 0001755237

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001559706

Filing Metadata

Form type
4
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 4:05 PM ET
Size
7.9 KB